- Home
- EDRY vs ALXO Comparison
EDRY vs ALXO Comparison
Compare EDRY & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDRY
- ALXO
- Stock Information
- Founded
- EDRY 2018
- ALXO 2015
- Country
- EDRY Greece
- ALXO United States
- Employees
- EDRY N/A
- ALXO N/A
- Industry
- EDRY Marine Transportation
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- EDRY Consumer Discretionary
- ALXO Health Care
- Exchange
- EDRY Nasdaq
- ALXO Nasdaq
- Market Cap
- EDRY 24.6M
- ALXO 28.3M
- IPO Year
- EDRY N/A
- ALXO 2020
- Fundamental
- Price
- EDRY $9.70
- ALXO $0.46
- Analyst Decision
- EDRY
- ALXO Strong Buy
- Analyst Count
- EDRY 0
- ALXO 6
- Target Price
- EDRY N/A
- ALXO $3.54
- AVG Volume (30 Days)
- EDRY 3.1K
- ALXO 512.2K
- Earning Date
- EDRY 05-23-2025
- ALXO 05-08-2025
- Dividend Yield
- EDRY N/A
- ALXO N/A
- EPS Growth
- EDRY N/A
- ALXO N/A
- EPS
- EDRY N/A
- ALXO N/A
- Revenue
- EDRY $61,083,227.00
- ALXO N/A
- Revenue This Year
- EDRY N/A
- ALXO N/A
- Revenue Next Year
- EDRY $42.57
- ALXO N/A
- P/E Ratio
- EDRY N/A
- ALXO N/A
- Revenue Growth
- EDRY 28.35
- ALXO N/A
- 52 Week Low
- EDRY $8.00
- ALXO $0.44
- 52 Week High
- EDRY $24.84
- ALXO $17.50
- Technical
- Relative Strength Index (RSI)
- EDRY 58.49
- ALXO 38.73
- Support Level
- EDRY $8.78
- ALXO $0.41
- Resistance Level
- EDRY $8.85
- ALXO $0.55
- Average True Range (ATR)
- EDRY 0.19
- ALXO 0.05
- MACD
- EDRY 0.15
- ALXO 0.00
- Stochastic Oscillator
- EDRY 89.06
- ALXO 22.76
About EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulks such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.